Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Vomiting 1Stomach Neoplasms 1Spinal Cord Compression 1Prostatic Neoplasms 1Pancreatitis 1Pancreatic Neoplasms 1Ototoxicity 1Osteosarcoma 1Helicobacter Infections 1Gastritis, Atrophic 1Duodenal Neoplasms 1Delayed Bleeding 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumours 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × Pantoprazole × Clear all
NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Children's Hospital of Philadelphia

Phase 2 Completed
13 enrolled 15 charts
Sarcoma

Ototoxicity, Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡